Dacomitinib as a retreatment for advanced non-small cell lung cancer patient with an uncommon EGFR mutation.
In non-small cell lung cancer (NSCLC), uncommon epidermal growth factor receptor (EGFR) mutations are mutations other than Ex19 deletion and Ex21 L858R, which are common mutations highly sensitive to EGFR-tyrosine kinase inhibitors. Afatinib, a second-generation EGFR-tyrosine kinase inhibitor, has been shown to be effective in patients with uncommon mutations. Dacomitinib, another second-generation EGFR-tyrosine kinase inhibitor, has not previously been shown to be effective in patients with uncommon mutations. Here, we report the efficacy of dacomitinib for uncommon EGFR mutations in a 71-year-old woman diagnosed with metastatic lung adenocarcinoma with uncommon EGFR mutation (Ex18 G719A). Afatinib was administered as the first-line treatment, and a remarkable antitumor effect was observed. However, the tumor grew after 14 months. Pemetrexed plus carboplatin followed by pemetrexed, docetaxel, atezolizumab and S-1 were performed in sequence. Although approximately four years had passed since the start of treatment, her physical condition was good. The patient started dacomitinib as the sixth-line treatment. Lesions were markedly reduced and treatment with dacomitinib was continued for 7.8 months. Dacomitinib is a possible treatment option for NSCLC with uncommon mutations.
['Morita|Ayako|A|', 'Hosokawa|Shinobu|S|0000-0001-5645-2434', 'Yamada|Kotaro|K|', 'Umeno|Takahiro|T|', 'Kano|Hirohisa|H|', 'Kayatani|Hiroe|H|', 'Shiojiri|Masaaki|M|', 'Sakugawa|Makoto|M|', 'Bessho|Akihiro|A|']
D000368:Aged D002289:Carcinoma, Non-Small-Cell Lung D066246:ErbB Receptors D005260:Female D006801:Humans D008175:Lung Neoplasms D009154:Mutation D052999:Quinazolinones
dacomitinib non-small cell lung cancer uncommon EGFR mutation afatinib EGFR-TKI re-administration